Background Evidence of comparative benefits of long-acting injectable antipsychotics (LAIs)
versus oral antipsychotics for schizophrenia has been inconsistent across study designs …

Background Schizophrenia is a common, severe, and usually chronic disorder. Maintenance
treatment with antipsychotic drugs can prevent relapse but also causes side-effects. We …

Compared with oral antipsychotics (OAPs), long-acting injectable antipsychotics (LAIs)
should improve medication adherence and reduce relapses in schizophrenia. However …

Background: While long-acting injectable antipsychotics (LAIs) are hoped to reduce high
relapse rates in schizophrenia, recent randomized controlled trials (RCTs) challenged the …

Background Although continuous treatment with antipsychotics is still recommended as the
gold standard treatment paradigm for all patients with schizophrenia, some clinicians …

Objective: Recent, large, randomized controlled trials (RCTs) showed no benefit of long-
acting injectable (LAI) antipsychotics over oral antipsychotics in preventing relapse in …

Background Dose reduction of antipsychotic maintenance treatment in individuals with
schizophrenia could be desirable to minimise adverse effects, but evidence for this strategy …

Background Schizophrenia is a severe psychiatric disorder with periods of remission and
relapse. As discontinuation of antipsychotic medication is the most important reason for …

Second‐generation antipsychotics (SGAs) are recommended for maintenance treatment in
schizophrenia. However, comparative long‐term effectiveness among SGAs is unclear. Here …

According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based …